In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 4, 2000, Pages 938-942

  Andes, D ^a   Van Ogtrop, M ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCYTOSINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SENSITIVITY; FEMALE; HOSPITAL INFECTION; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

ALKYLATING AGENTS; ANIMALS; ANTIFUNGAL AGENTS; AREA UNDER CURVE; CANDIDA ALBICANS; CANDIDIASIS; COLONY COUNT, MICROBIAL; CYCLOPHOSPHAMIDE; FEMALE; FLUCYTOSINE; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; NEUTROPENIA;

EID: 0034063522     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.4.938-942.2000     Document Type: Article

References (30)

1. Anaissie, E. J., N. C. Karyotakis, R. Hachem, M. C. Dignani, J. H. Rex, and V. Paetznick. 1994. Correlation between in vitro and in vivo activity of antifungal agents against Candida species. J. Infect. Dis. 170:384-389.
2. Andes, D., and M. van Ogtrop. 1999. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. Antimicrob. Agents Chemother. 43:2116-2120.
3. Atkinson, B. A., C. Bouthet, R. Bocanegra, A. Correa, M. F. Luther, and J. R. Graybill. 1995. Comparison of fluconazole, amphotericin B and flucytosine in treatment of a murine model of disseminated infection with Candida glabrata in immunocompromised mice. J. Antimicrob. Chemother. 35:631-540.
4. Banerjee, S. N., T. G. Emori, D. H. Culver, R. P. Gaynes, W. R. Jarvis, T. Horan, J. R. Edwards, J. S. Tolson, T. Henderson, and W. J. Martone. 1991. Secular trends in nosocomial primary blood stream infections in the United States, 1980-1989. Am. J. Med. 91(Suppl. 3B):86-89.
5. Bennett, J. E., W. E. Dismukes, R. J. Duma, G. Medoff, M. A. Sande, H. Gallis, J. Leonard, B. T. Fields, M. Bradshaw, H. Haywood, Z. A. McGee, T. R. Cate, C. G. Cobs, J. F. Warner, and D. W. Alling. 1979. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N. Engl. J. Med. 301:126-131.
6. Blaser, J., B. B. Stone, M. C. Groner, and S. H. Zinner. 1987. Comparative study with enoxacin and netilmicin, a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob. Agents Chemother. 31: 1054-1060.
7. Craig, W. A., and S. Gudmundsson. 1996. Postantibiotic effect, p. 295-329. In V. Lorian (ed.), Antibiotics in laboratory medicine, 4th ed. Baltimore: The Williams & Wilkins Co., Baltimore, Md.
8. Craig, W. A., J. Redington, and S. C. Ebert. 1991. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. J. Antimicrob. Chemother. 27(Suppl. C):29-40.
9. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-12.
10. Craig, W. A., and D. Andes. 1996. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr. Infect. Dis. J. 15:955-962.
11. Cutler, R. E., A. D. Blair, and M. R. Kelly. 1978. Flucytosine kinetics in subjects with normal and impaired renal function. Clin. Pharmacol. Ther. 24:333-342.
12. den Hollander, J. G., J. W. Mouton, and H. A. Verbrugh. 1998. Use of pharmacodynamic parameters to predict efficacy of combination therapy by using fractional inhibitory concentration kinetics. Antimicrob. Agents Chemother. 42:744-748.
13. Edwards, J. E., and Conference Participants. 1997. International Conference for the Development of a Consensus on the Management and Prevention of Severe Candida Infections. Clin. Infect. Dis. 25:43-59.
14. Francis, P., and T. J. Walsh. 1992. Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. Clin. Infect. Dis. 15:1003-1018.
15. Georgeopapadakou, N. H., and T. J. Walsh. 1996. Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrob. Agents Chemother. 40:279-291.
16. Graybill, J. R., L. K. Najvar, J. D. Holmberg, and M. F. Luther. 1995. Fluconazole, D0870, and flucytosine treatment of disseminated Candida tropicalis infections in mice. Antimicrob. Agents Chemother. 39:924-929.
17. Karytotakis, N. C., and E. J. Anaissie. 1996. Efficacy of continuous flucytosine infusion against Candida lusitaniae in experimental hematogenous murine candidiasis. Antimicrob. Agents Chemother. 40:2907-2908.
18. Kauffman, C. A., and P. T. Frame. 1977. Bone marrow toxicity associated with 5-fluorocytosine therapy. Antimicrob. Agents Chemother. 11:244-247.
19. Moore, R. D., P. S. Lietman, and C. R. Smith. 1987. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J. Infect. Dis. 155:93-99.
20. Mouton, J. W., M. L. van Ogtrop, D. Andes, and W. A. Craig. 1999. Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo. Antimicrob Agents Chemother. 43:2473-2478.
21. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing for yeast; approved standard. M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
22. Polak, A. 1989. Combination therapy for systemic mycosis. Infection 17:203-208.
23. Shadomy, S., A. Espinel-Ingroff, and Y. Cartwright. 1985. Laboratory studies with antifungal agents: susceptibility tests and bioassays, p. 991-999. In E. H. Lennette, A. Balows, W. J. Hausler, Jr., and H. J. Shadomy (ed.), Manual of clinical microbiology, 4th ed. American Society for Microbiology, Washington, D.C.
24. Smego, R. A., J. R. Perfect, and D. T. Durack. 1984. Combined therapy with amphotericin B and 5-fluorocytosine for candida meningitis. Rev. Infect. Dis. 6:791-800.
25. Stiller, R. L., J. E. Bennett, H. J. Scholer, M. Wall, A. Polak, and D. A. Stevens. 1983. Correlation of in vitro susceptibility test results with in vivo response: flucytosine therapy in a systemic candidiasis model. J. Infect. Dis. 147:1070-1077.
26. Thaler, M., J. Bacher, T. O'Leary, and P. A. Pizzo. 1988. Evaluation of single-drug and combination antifungal therapy in an experimental model of candidiasis in rabbits with prolonged neutropenia. J. Infect. Dis. 158:80-88.
27. Viviani, M. A. 1995. Flucytosine - what is its future? J. Antimicrob. Chemother. 35:241-244.
28. Vogelman, B., S. Gudmundsson, J. Turnidge, J. Leggett, and W. A. Craig. 1988. In vivo postantibiotic effect in a thigh infection in neutropenic mice. J. Infect. Dis. 157:287-298.
29. Vogelman, B., S. Gudmundsson, J. Leggett, J. Turnidge, S. Ebert, and W. A. Craig. 1988. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J. Infect. Dis. 158:831-847.
30. Wey, S. B., M. Mori, M. A. Pfaller, R. F. Woolson, and R. P. Wenzel. 1988. Hospital acquired candidemia: the attributable mortality and excess length of stay. Arch. Intern. Med. 148:2642-2645.